Prevention of Late Recurrence: An Increasingly Important Target for Breast Cancer Research and Control.
作者信息
Negoita Serban, Ramirez-Pena Esmeralda
机构信息
Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
J Natl Cancer Inst. 2022 Mar 8;114(3):340-341. doi: 10.1093/jnci/djab203.
Abstract
摘要
相似文献
1
Prevention of Late Recurrence: An Increasingly Important Target for Breast Cancer Research and Control.预防晚期复发：乳腺癌研究与控制中日益重要的目标
J Natl Cancer Inst. 2022 Mar 8;114(3):340-341. doi: 10.1093/jnci/djab203.
2
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.预测雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌早期和晚期远处复发的临床病理因素
Breast Cancer. 2016 Nov;23(6):830-843. doi: 10.1007/s12282-015-0649-0. Epub 2015 Oct 14.
3
Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌病例中，癌干细胞标志物醛脱氢酶1在早期、晚期和无复发情况下的表达差异。
Breast Cancer Res. 2016 Jul 2;18(1):73. doi: 10.1186/s13058-016-0731-3.
4
Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌患者晚期复发的独特特征和转移行为：一家医院 10 年以上的经验。
Clin Breast Cancer. 2018 Dec;18(6):e1353-e1360. doi: 10.1016/j.clbc.2018.07.014. Epub 2018 Jul 24.
5
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者早期和晚期远处复发后的生存情况
Breast Cancer. 2017 May;24(3):473-482. doi: 10.1007/s12282-016-0730-3. Epub 2016 Sep 15.
6
The natural history of hormone receptor-positive breast cancer.激素受体阳性乳腺癌的自然病程。
Oncology (Williston Park). 2012 Aug;26(8):688-94, 696.
7
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.针对雌激素受体阴性乳腺癌的靶向异常 p70S6K 激活。
Cancer Prev Res (Phila). 2017 Nov;10(11):641-650. doi: 10.1158/1940-6207.CAPR-17-0106. Epub 2017 Sep 6.
8
Childbirth delay may reduce risk of an aggressive breast cancer.分娩延迟可能会降低侵袭性乳腺癌的风险。
Cancer. 2013 May 15;119(10):1767. doi: 10.1002/cncr.28139.
9
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.患者来源的管腔乳腺癌异种移植保留了激素受体异质性，并有助于确定独特的雌激素依赖性基因特征。
Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.
10
The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.雌激素受体：抗雌激素预防乳腺癌的合理靶点。
J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):401-13. doi: 10.1023/a:1018722502034.
引用本文的文献
1
Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up.低剂量阿司匹林使用与乳腺癌复发之间的关联：一项丹麦全国性队列研究，随访时间长达23年。
Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03112-3.
2
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials.CTS5在四项前瞻性、多中心、随机的ABCSG试验中的验证。
Breast. 2025 Apr;80:104415. doi: 10.1016/j.breast.2025.104415. Epub 2025 Feb 19.
3
Dormancy Leading to Late Recurrence in Breast Cancer: A Case of Hormone Receptor-Positive Supraclavicular Metastasis 10 Years After the Initial Treatment.休眠导致乳腺癌晚期复发：一例激素受体阳性锁骨上转移病例，初始治疗10年后出现转移
Cureus. 2024 Oct 16;16(10):e71586. doi: 10.7759/cureus.71586. eCollection 2024 Oct.
4
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?在辅助治疗的扩展环境下，CTS5 是否是一个有帮助的决策工具？
Breast Cancer Res Treat. 2024 Jun;205(2):227-239. doi: 10.1007/s10549-023-07186-6. Epub 2024 Jan 25.
5
Determinants of response to CDK4/6 inhibitors in the real-world setting.真实世界中对CDK4/6抑制剂反应的决定因素。
NPJ Precis Oncol. 2023 Sep 13;7(1):90. doi: 10.1038/s41698-023-00438-0.
6
Prevention and Therapy of Metastatic HER-2 Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine.用人源HER-2病毒样颗粒疫苗预防和治疗转移性HER-2乳腺癌
Biomedicines. 2022 Oct 20;10(10):2654. doi: 10.3390/biomedicines10102654.
本文引用的文献
1
The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis.乳腺癌患者首次诊断后 10-32 年内的复发情况。
J Natl Cancer Inst. 2022 Mar 8;114(3):391-399. doi: 10.1093/jnci/djab202.
2
Validation of an Algorithm to Ascertain Late Breast Cancer Recurrence Using Danish Medical Registries.使用丹麦医学登记处确定晚期乳腺癌复发的算法验证
Clin Epidemiol. 2020 Oct 14;12:1083-1093. doi: 10.2147/CLEP.S269962. eCollection 2020.
3
Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis.使用乳腺 MRI 对有乳腺癌个人史的女性进行第二乳腺癌事件监测的系统评价和荟萃分析。
Breast Cancer Res Treat. 2020 Jun;181(2):255-268. doi: 10.1007/s10549-020-05637-y. Epub 2020 Apr 17.
4
Recurrence rates and long-term survival factors in young women with breast cancer.年轻女性乳腺癌的复发率和长期生存因素。
Saudi Med J. 2020 Apr;41(4):393-399. doi: 10.15537/smj.2020.4.24987.
5
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.《NCCN 肿瘤学临床实践指南：乳腺癌》第 3.2020 版
J Natl Compr Canc Netw. 2020 Apr;18(4):452-478. doi: 10.6004/jnccn.2020.0016.
6
A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data.基于行政数据评估人群乳腺癌复发的系统评价。
J Natl Cancer Inst. 2020 Oct 1;112(10):979-988. doi: 10.1093/jnci/djaa050.
7
Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses.DCIS 后浸润性乳腺癌复发的预测因素：系统评价和荟萃分析。
Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):835-845. doi: 10.1158/1055-9965.EPI-18-0976. Epub 2019 Apr 25.
8
Prevalence and factors associated with unmet needs in post-treatment cancer survivors: A systematic review.治疗后癌症幸存者未满足需求的流行率及相关因素：系统综述。
Eur J Cancer Care (Engl). 2019 May;28(3):e13060. doi: 10.1111/ecc.13060. Epub 2019 Apr 22.
9
Factors influencing breast cancer outcomes in Australia: A systematic review.影响澳大利亚乳腺癌结局的因素：系统评价。
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13038. doi: 10.1111/ecc.13038. Epub 2019 Mar 27.
10
Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review.孤立局部乳腺癌复发和对侧乳腺癌的发生率：系统评价。
Breast. 2018 Jun;39:70-79. doi: 10.1016/j.breast.2018.03.011. Epub 2018 Apr 2.
Zotero 插件